

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues relating to protected population groups were raised during consultation. However it was mentioned that expert multi-disciplinary teams are not available in all areas of the UK, requiring travel

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No change to the scope was considered.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change to the scope was considered.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No equality issues relating to protected population groups were raised during

consultation. However it was mentioned that expert multi-disciplinary teams are not available in all areas of the UK, requiring travel. The clinical expert present at the meeting noted that tocilizumab did not need to be given in a specialist centre. No further issues were raised at the workshop.

No change to the scope was considered.

Approved by Associate Director:Frances Sutcliffe.....

Date: 11/02/2011